Uveitic macular edema: a stepladder treatment paradigm
@article{Preble2015UveiticME, title={Uveitic macular edema: a stepladder treatment paradigm}, author={Janine M. Preble and Charles Stephen Foster}, journal={Clinical investigation}, year={2015}, volume={5}, pages={509-517} }
The purpose of this review is to evaluate the treatment modalities that are commonly employed for the treatment of uveitis-related macular edema. Herein, the different drug classes used to treat the condition are described. In addition, the effectiveness, benefits and risks of the different routes of drug administration are discussed. Although some treatments have been evaluated in prospective clinical trials, most clinical research has been retrospective in nature. Thus, there is a need for…
6 Citations
Emerging therapies in the management of macular edema: a review
- Medicine, BiologyF1000Research
- 2019
Three main causes ofacular edema are focused on: diabetic retinopathy, retinal vein occlusion, and uveitis, and several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy.
Quantitative Analysis of Uveitis Macular Edema in Multiple Sclerosis Patients Receiving Deep Posterior Sub-Tenon Triamcinolone Acetonide Injection
- MedicineOphthalmic Research
- 2017
Posterior sub-Tenon injection of triamcinolone acetonide significantly improved visual acuity and decrease macular edema in patients with intermediate uveitis associated with multiple sclerosis.
Synergistic Effect of Combined Sub-Tenon Triamcinolone and Intravitreal Anti-VEGF Therapy for Uveitic Macular Edema
- MedicineDrug design, development and therapy
- 2022
Combined intravitreal anti-VEGF and STA is superior to STA alone for reduction of UME and visual restoration and did not increase risk for steroid-induced elevation of intraocular pressure over 6 months.
Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer’s perspective
- MedicineBMJ Open Ophthalmology
- 2021
NIU is associated with substantial clinical and economic burden, particularly when UME is present, and a trend of increasing healthcare costs with increasing vision loss was observed.
References
SHOWING 1-10 OF 65 REFERENCES
Etiology and treatment of the inflammatory causes of cystoid macular edema
- MedicineJournal of inflammation research
- 2009
The mechanism of ocular inflammation in cystoid macular edema is discussed with a particular focus on the inflammatory causes: post-operative, uveitic, and after laser procedures.
Cystoid macular edema
- MedicineClinical ophthalmology
- 2008
The goal of this paper is to review the current status of this treatment for macular edema due to diabetic maculopathy, central retinal vein occlusion and post-cataract surgery and the results of recent multicenter clinical trials are quoted.
The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema
- MedicineJournal of ophthalmology
- 2014
Bvacizumab was effective in the management of UME associated with both infectious and noninfectious uveitides and had no immunosuppressive effect against infectious agents.
Intravitreal steroids for macular edema: the past, the present, and the future.
- MedicineSurvey of ophthalmology
- 2008
Tocilizumab treatment for refractory uveitis-related cystoid macular edema
- MedicineGraefe's Archive for Clinical and Experimental Ophthalmology
- 2013
These data suggest that TCZ is effective for treating CME in otherwise treatment-refractory cases of uveitis.
Macular edema : a practical approach
- Medicine
- 2010
"Macular Edema - A Practical Approach" provides the ophthalmologist with a synthesis of knowledge to diagnose, to determine etiology, and to offer the patient viable treatment options for his benefit.
Medical treatment of macular edema in patients with uveitis
- MedicineDocumenta Ophthalmologica
- 2004
CME, a vision threatening complication of uveitis, respond fairly well to medical treatment; however, the best VA is achieved after several months, while the improvement in VA did not differ markedly among the three treatment groups.
Infliximab for chronic cystoid macular edema associated with uveitis.
- MedicineAmerican journal of ophthalmology
- 2004